Pfizer's Varenicline NDA For Smoking Cessation Includes Comparison To GSK’s Zyban
This article was originally published in The Pink Sheet Daily
Executive Summary
In Phase III studies, 44% of varenicline patients quit smoking by the end of a 12-week treatment period, compared to 30% of patients on GlaxoSmithKline’s Zyban, Pfizer reports.
You may also be interested in...
Pfizer's Champix Receives Six-Month Priority Review
Pfizer submitted the NDA for its smoking cessation therapy varenicline in November.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability